Alimera Sciences (NASDAQ:ALIM) has been given a consensus broker rating score of 1.00 (Strong Buy) from the two analysts that cover the stock, Zacks Investment Research reports. Two research analysts have rated the stock with a strong buy rating.
Brokerages have set a 1 year consensus target price of $4.00 for the company and are expecting that the company will post ($0.04) earnings per share for the current quarter, according to Zacks. Zacks has also given Alimera Sciences an industry rank of 183 out of 265 based on the ratings given to its competitors.
Several research firms have recently weighed in on ALIM. Zacks Investment Research downgraded shares of Alimera Sciences from a “buy” rating to a “hold” rating in a research note on Monday, April 2nd. HC Wainwright reiterated a “buy” rating and issued a $5.00 target price on shares of Alimera Sciences in a research note on Monday, January 22nd.
Alimera Sciences (NASDAQ:ALIM) last announced its quarterly earnings data on Wednesday, February 28th. The biopharmaceutical company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.03) by ($0.07). The business had revenue of $9.14 million for the quarter, compared to analyst estimates of $9.60 million. analysts forecast that Alimera Sciences will post -0.06 earnings per share for the current year.
In related news, CEO C. Daniel Myers sold 52,900 shares of the business’s stock in a transaction that occurred on Friday, January 19th. The shares were sold at an average price of $1.20, for a total transaction of $63,480.00. Following the completion of the transaction, the chief executive officer now owns 101,511 shares of the company’s stock, valued at $121,813.20. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, SVP Philip Ashman sold 25,500 shares of the business’s stock in a transaction that occurred on Wednesday, January 17th. The shares were sold at an average price of $1.23, for a total transaction of $31,365.00. Following the transaction, the senior vice president now directly owns 38,250 shares of the company’s stock, valued at approximately $47,047.50. The disclosure for this sale can be found here. Insiders sold 184,704 shares of company stock valued at $224,432 in the last quarter. Corporate insiders own 14.70% of the company’s stock.
An institutional investor recently raised its position in Alimera Sciences stock. Stonepine Capital Management LLC boosted its position in shares of Alimera Sciences (NASDAQ:ALIM) by 158.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 477,226 shares of the biopharmaceutical company’s stock after acquiring an additional 292,399 shares during the period. Alimera Sciences accounts for about 0.4% of Stonepine Capital Management LLC’s holdings, making the stock its 21st biggest position. Stonepine Capital Management LLC owned 0.69% of Alimera Sciences worth $644,000 at the end of the most recent reporting period. 46.11% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: “Zacks: Alimera Sciences (ALIM) Receives Consensus Recommendation of “Strong Buy” from Brokerages” was first posted by Ticker Report and is the sole property of of Ticker Report. If you are viewing this article on another site, it was copied illegally and reposted in violation of United States & international trademark and copyright law. The correct version of this article can be read at https://www.tickerreport.com/banking-finance/3342008/zacks-alimera-sciences-alim-receives-consensus-recommendation-of-strong-buy-from-brokerages.html.
Alimera Sciences Company Profile
Alimera Sciences, Inc (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alimera Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences and related companies with MarketBeat.com's FREE daily email newsletter.